Devyser announced the launch of next generation chimerism analysis solution, strengthening its offering in post-transplant monitoring
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
One severe complication following solid organ transplantation is antibody- and/or cell-mediated rejections of the graft. Early detection of rejection may therefore be of paramount importance to improve graft survival following solid organ transplantation. The present study was conducted to determine the monitoring capability and clinical utility of the Devyser assay designed for the sensitive detection of dd-cfDNA (donor-derived cell-free DNA) in patients following kidney transplantation.
One Lambda™ Devyser Chimerism Plus is a next generation solution for chimerism analysis following...
Read More
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a tender in...
Read More
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing...
Read More
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has...
Read More